Aprobación del inhibidor dual de TYK2/JAK Lisraya (brepocitinib) por parte de la FDA para tratar la dermatomiositis, una enfermedad autoinmune rara que provoca debilidad muscular progresiva y erupciones cutáneas inflamatorias.

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults Lisraya is the first FDA-approved oral treatment option for patients with dermatomyositis, addressing the high unmet need for this rare disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-drug-indicated-treat-dermatomyositis-adults?utm_medium=email&_hsenc=p2ANqtz--l6c6O_0G1l_DLKChPzNuqccxBLal-lQLKK8GEXk2Diim--iDUTgrWfCKGFYJJxcOy9I5rNT74Kz9oe1xD89XZhsw0DA&_hsmi=144840094&utm_content=144848639&utm_source=hs_email